Mixed features crisis and rapid-cycling reformulation (MEQ)

(i) Formulation of episode and course. Current episode: bipolar I disorder, current episode manic, with mixed features — full manic syndrome (decreased sleep need, pressure, irritability, spending) plus depressive cognitions and active suicidal ideation. Course specifier: rapid cycling is supported if the past-year count is at least four full episodes (here two manias + three depressions meets the bar). Sertraline monotherapy is a likely cycle accelerator and polarity-unsafe treatment. Negative UDS and normal observations reduce but do not eliminate medical differentials; still complete baseline bloods/ECG before re-starting lithium/SGA. Incomplete inter-episode recovery indicates high morbidity phenotype.[4][5]

(ii) Acute risk and legal principles. This is a high-risk mixed phenotype (depression + energy + means research). Same-day senior review; likely admission. Means restriction, continuous observation as indicated, no unescorted leave initially, partner involvement with consent. Assess capacity for treatment decisions; if incapacitous with serious risk, use least-restrictive involuntary pathway under local statute (do not invent foreign section numbers). Document risk formulation, not only a score.[4]

(iii) Pharmacotherapy. Stop sertraline (taper only if clinically needed to avoid discontinuation effects — in severe mixed mania, prompt cessation under cover is often appropriate). Start polarity-safe cover after baselines: e.g. olanzapine 10–15 mg oral at night (titrate toward 10–20 mg) plus lithium re-initiation at 450–900 mg/day with plan for 12-hour trough roughly 0.8–1.2 mmol/L in acute mania, level at 5–7 days; or add/substitute valproate if lithium unsuitable and pregnancy risk managed. Combination is reasonable in severe mixed mania. Short-term lorazepam for sleep/arousal per protocol. Monitor metabolic parameters, sedation, renal/thyroid/calcium for lithium. Do not replace sertraline with another antidepressant monotherapy. STEP-BD showed adjunctive antidepressants did not beat mood stabiliser plus placebo for durable recovery; monotherapy is even less defensible.[1][3][4]

(iv) 12-month plan. Confirm rapid-cycling chart prospectively. Re-check TFT and treat thyroid disease if present. Maintenance: continue effective acute regimen into early recovery then simplify toward lithium-first prevention when tolerated — BALANCE supports lithium over valproate monotherapy, with combination also effective.[2] Psychoeducation, sleep regularity, IPSRT or CBT-bipolar, substance review, written early-warning signs with partner, crisis contacts, contraceptive counselling if valproate ever considered, and structured outpatient follow-up with metabolic monitoring for SGA.[4][5]